Jefferies downgraded Instil Bio to Hold from Buy with a price target of $11, up from $5. The company is undergoing strategic restructuring and has discontinued ITIL-306 clinical development, the analyst tells investors in a research note. The firm updated its model to reflect the reverse stock split and awaits a future update.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>